{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:30:57Z","timestamp":1776875457302,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s11126-006-7963-9","type":"journal-article","created":{"date-parts":[[2006,1,5]],"date-time":"2006-01-05T12:06:02Z","timestamp":1136462762000},"page":"81-95","source":"Crossref","is-referenced-by-count":69,"title":["Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia"],"prefix":"10.1007","volume":"77","author":[{"given":"Deanna L.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7963_CR1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","volume":"50","author":"RR Conley","year":"2001","unstructured":"Conley RR, Kelly DL: Management of treatment-resistant schizophrenia. Biological Psychiatry 50:898\u2013911, 2001.","journal-title":"Biological Psychiatry"},{"key":"7963_CR2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"M Chakos","year":"2001","unstructured":"Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 158:518\u2013526, 2001.","journal-title":"American Journal of Psychiatry"},{"key":"7963_CR3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.schbul.a033463","volume":"26","author":"S-A Chong","year":"2000","unstructured":"Chong S-A, Remington G: Clozapine augmentation: Safety and efficacy. Schizophrenia Bulletin 26:421\u2013440, 2000.","journal-title":"Schizophrenia Bulletin"},{"key":"7963_CR4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.npp.1300023","volume":"28","author":"DE Casey","year":"2003","unstructured":"Casey DE, Daniel DG, Wassef AA, et al: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182\u2013192, 2003","journal-title":"Neuropsychopharmacology"},{"key":"7963_CR5","first-page":"17","volume":"100","author":"I Afaq","year":"2002","unstructured":"Afaq I, Riaz J, Sedky K, et al: Divalproex as a calmative adjunct for aggressive schizophrenic patients. Journal of the Kentucky Medical Association 100:17\u201322, 2002.","journal-title":"Journal of the Kentucky Medical Association"},{"key":"7963_CR6","first-page":"199","volume":"11","author":"A Morinigo","year":"1989","unstructured":"Morinigo A, Martin J, Gonzalex S, et al: Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside Jounal of Clinical Psychiatry 11:199\u2013207, 1989.","journal-title":"Hillside Jounal of Clinical Psychiatry"},{"key":"7963_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-2007-979312","volume":"31","author":"M Dose","year":"1998","unstructured":"Dose M, Hellweg R, Yassouridis A, et al: Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31:122\u2013125, 1998.","journal-title":"Pharmacopsychiatry"},{"key":"7963_CR8","doi-asserted-by":"crossref","unstructured":"Littrell KH, Petty RG, Hilligoss NM, et al: Valproate for hostility in schizophrenia patients. Journal of Clinical Psychiatry 65:134, 2004.","DOI":"10.4088\/JCP.v65n0122d"},{"key":"7963_CR9","doi-asserted-by":"crossref","unstructured":"Chong S-A, Tan C-H, Lee E-L, et al: Augmentation of risperidone with valproic acid. Journal of Clinical Psychiatry 59:430, 1998.","DOI":"10.4088\/JCP.v59n0806a"},{"key":"7963_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004714-200006000-00011","volume":"20","author":"AA Wassef","year":"2000","unstructured":"Wassef AA, Dott SG, Harris A, et al: Randomized placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of Clinical Psychopharmacology 20:357\u2013361, 2000.","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"7963_CR11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W Loscher","year":"2002","unstructured":"Loscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs 16:669\u2013694, 2002.","journal-title":"CNS drugs"},{"key":"7963_CR12","first-page":"74","volume":"2","author":"L Citrome","year":"2003","unstructured":"Citrome L: Schizophrenia and valproate. Psychopharmacology Bulletin 37 suppl 2:74\u201388, 2003.","journal-title":"Psychopharmacology Bulletin 37 suppl"},{"key":"7963_CR13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4088\/JCP.v65n0601","volume":"65","author":"SM Stahl","year":"2004","unstructured":"Stahl SM: Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. Journal of Clinical Psychiatry 65:738\u2013739, 2004.","journal-title":"Journal of Clinical Psychiatry"},{"key":"7963_CR14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ps.51.5.634","volume":"51","author":"L Citrome","year":"2000","unstructured":"Citrome L, Levine J, Allingham B: Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51:634\u2013638, 2000.","journal-title":"Psychiatric Services"},{"key":"7963_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1017\/S1461145703003870","volume":"7","author":"S Bender","year":"2004","unstructured":"Bender S, Linka T, Wolstein J, et al: Safety and efficacy of combined clozapine-lithium pharmacotherapy. International Journal of Neuropsychopharmacology 7:59\u201363, 2004.","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"7963_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","volume":"65","author":"S Leucht","year":"2004","unstructured":"Leucht S, Kissling W, McGrath J: Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry. 65(2):177\u2013186, 2004.","journal-title":"Journal of Clinical Psychiatry"},{"key":"7963_CR17","first-page":"255","volume":"55","author":"JC Kando","year":"1994","unstructured":"Kando JC, Tohen M, Castillo J, et al: Concurrent use of clozapine and valproate in affective and psychotic disorders. Journal of Clinical Psychiatry 55:255\u2013257, 1994.","journal-title":"Journal of Clinical Psychiatry"},{"key":"7963_CR18","doi-asserted-by":"crossref","unstructured":"Bender SA, Wolstein JR, Ortmann K, et al: Treatment of schizophrenia and schizoaffective disorder with a combination of clozapine and lithium. European Neuropsychopharmacology 6:200, 1996.","DOI":"10.1016\/0924-977X(96)88243-5"},{"key":"7963_CR19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ps.55.3.290","volume":"55","author":"L Citrome","year":"2004","unstructured":"Citrome L, Casey DE, Daniel DG, et al: Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services 55:290\u2013294, 2004.","journal-title":"Psychiatric Services"},{"key":"7963_CR20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4088\/JCP.v65n0601","volume":"65","author":"SM Stahl","year":"2004","unstructured":"Stahl SM: Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbamazepine and actions at voltage-gated sodium channels. Journal of Clinical Psychiatry 65:738\u2013739, 2004.","journal-title":"Journal of Clinical Psychiatry"},{"key":"7963_CR21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","volume":"56","author":"I Kremer","year":"2004","unstructured":"Kremer I, Vass A, Gorelik I, et al: Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biological Psychiatry 56:441\u2013446, 2004.","journal-title":"Biological Psychiatry"},{"key":"7963_CR22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","volume":"63","author":"JM Meyer","year":"2002","unstructured":"Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 63:425\u2013433, 2002.","journal-title":"Journal of Clinical Psychiatry"},{"key":"7963_CR23","unstructured":"Jafari M, Jiang P, Casey DE: Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine. Presented at the American Psychiatric Association, New York, NY, May 2004"},{"key":"7963_CR24","first-page":"1357","volume":"4","author":"S Horie","year":"1984","unstructured":"Horie S and Suga T: Enhancement of perioxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochemical Pharmacology 4:1357\u20131385, 1984.","journal-title":"Biochemical Pharmacology"},{"key":"7963_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/bj2720251","volume":"272","author":"JP Bolanos","year":"1990","unstructured":"Bolanos JP, Medina JM, Williamson DH: Inhibition of sterol but fatty acid synthesis by valproate in developing rat brain in vivo. Biochemical Journal 272:251\u2013253, 1990.","journal-title":"Biochemical Journal"},{"key":"7963_CR26","first-page":"50","volume":"10","author":"T Nikolaos","year":"2004","unstructured":"Nikolaos T, Stylianos G, Chryssoula N, et al: The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Medical Science Monitor 10:50\u201352, 2004.","journal-title":"Medical Science Monitor"},{"key":"7963_CR27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","volume":"157","author":"DC Henderson","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 157:975\u2013981, 2000.","journal-title":"American Journal of Psychiatry"},{"key":"7963_CR28","first-page":"1520","volume":"151","author":"MS Koval","year":"1994","unstructured":"Koval MS, Rames LJ, Christie S: Diabetic ketoacidos associated with clozapine treatment. American Journal of Psychiatry 151:1520\u20131521, 1994.","journal-title":"American Journal of Psychiatry"},{"key":"7963_CR29","first-page":"737","volume":"153","author":"GA Peterson","year":"1996","unstructured":"Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment. American Journal of Psychiatry. 153:737\u2013738, 1996.","journal-title":"American Journal of Psychiatry."},{"key":"7963_CR30","doi-asserted-by":"crossref","unstructured":"Ananth J, Johnson KM, Levander EM, et al: Diabetic ketoacidosis, neuroleptic syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. Journal of Clinical Psychiatry 65:724, 2004.","DOI":"10.4088\/JCP.v65n0520d"},{"key":"7963_CR31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2007-1018745","volume":"15","author":"GR Jones","year":"1983","unstructured":"Jones GR, Lazarus JH, Davies CJ, et al: The effect of short term lithium carbonate in Type II diabetes mellitus. Hormone Metabolism Research 15:422\u2013424, 1983.","journal-title":"Hormone Metabolism Research"},{"key":"7963_CR32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/ajp.153.5.727","volume":"153","author":"GA Peterson","year":"1996","unstructured":"Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment. Amerian Journal of Psychiatry 153:727\u2013728, 1996.","journal-title":"Amerian Journal of Psychiatry"},{"key":"7963_CR33","doi-asserted-by":"crossref","unstructured":"Boylan LS, Labovitz DL: Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia. Neuropsychopharmacology 29:636, 2004.","DOI":"10.1038\/sj.npp.1300368"},{"key":"7963_CR34","first-page":"297","volume":"86","author":"AC Altamura","year":"1986","unstructured":"Altamura AC, Baile R, Mauri M, et al: Valpromide (Depamide) in the treatment of acute psychotic states. Open clinical study. Acta Psychiatrica Belgium 86:297\u2013304, 1986.","journal-title":"Open clinical study. Acta Psychiatrica Belgium"},{"key":"7963_CR35","unstructured":"Negron AE: Divalproex sodium extended release (Depakote ER) for the acute treatment of schizophrenia: a retrospective chart review. Presented at the 44 Annual NCDEU Meeting, Phoenix, Arizona, June 1\u20134, 2004."},{"key":"7963_CR36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","volume":"21","author":"G Facciola","year":"1999","unstructured":"Facciola G, Avenoso A, Scordo MG, et al: Small effects of valproic acid on plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Therapeutic Drug Monitoring 21:341\u2013345, 1999.","journal-title":"Therapeutic Drug Monitoring"},{"key":"7963_CR37","first-page":"650","volume":"152","author":"LP Longo","year":"1995","unstructured":"Longo LP, Salzman C: Valproic acid effects on serum concentrations of clozapine and norclozapine. American Journal of Psychiatry 152:650\u2013651, 1995.","journal-title":"American Journal of Psychiatry"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-006-7963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-006-7963-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-006-7963-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:24:50Z","timestamp":1559359490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-006-7963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["7963"],"URL":"https:\/\/doi.org\/10.1007\/s11126-006-7963-9","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}